Solventum Corporation (SOLV)

Solventum Corp. began trading on the NYSE under the ticker "SOLV" on April 1, 2024, and was added to the S&P 500 index. As of April 6, 2026, the share price was $63.25, a 3.17% decline over the past year. Solventum reported its Q4 2025 earnings on February 26, 2026, and completed the acquisition of Acera Surgical in December 2025. The sale of its Purification & Filtration business to Thermo Fisher Scientific Inc. was completed in September 2025. Analyst opinions are mixed, and the company announced a $1 billion share repurchase program beginning in January 2026.

Information regarding specific demand seasonality for Solventum Corp.'s products and services is limited. Normal manufacturing seasonality was mentioned as impacting gross margin in Q3 2024, but detailed seasonal patterns were not explicitly provided.

Solventum Corp. is a global healthcare company that spun off from 3M on April 1, 2024, and is headquartered in Maplewood, Minnesota. It operates in the Medical Instruments & Supplies, Medical - Care Facilities, and Other Healthcare Services industries, utilizing material science, data science, and digital capabilities. Solventum manages its operations through three business segments: MedSurg, which focuses on advanced wound care, infection prevention, and surgical solutions; Dental Solutions, which provides restorative, prevention, and orthodontic solutions; and Health Information Systems (HIS), which delivers software solutions and services to improve care and healthcare reimbursement.

Solventum has a significant global presence with approximately 22,000 employees and operations in 38 countries. The company serves over 100,000 customers and channel partners in more than 90 countries worldwide, with a major revenue contribution from the United States.

Solventum emphasizes its trusted and recognized brands and premium brand positioning within the healthcare industry, with over 70 years of innovation. The company is in the process of removing the 3M logo from its products by 2027, involving significant logistics and marketing costs. The company highlights its commitment to quality, innovation, and customer satisfaction.

Institutional investors hold a significant portion of Solventum Corp., controlling 73% of the company's shares as of January 11, 2026. Major institutional owners include Vanguard Group Inc., BlackRock, Inc., and Trian Fund Management, L.P. 3M Company initially retained a 19.9% stake with plans to divest it within five years, and 80.1% of Solventum's stock was distributed to 3M shareholders during the spin-off. Retail investors collectively own 12% of the company.